Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.

Bold Capital Partners

Physician Partners,  give you the power to transform lives.  Working together as a team to shape the future of healthcare, they are at the forefront of innovation and best practices to improve the health of their communities. Their team provides the platform, technology solutions and new health programs in a collaborative environment to our primary care providers with the sole purpose of achieving Better Health.  Their commitment, their passion and their culture sets them apart from others and is the cornerstone of everything they do. Their team settles for nothing less than a new and profoundly better way of delivering truly proactive health care rather than simply building a better version of the same old reactive sick care model that serves our communities today.

Better Health Group

Nomad Capital Partners is a provider of growth capital to seed and fast growing startup enterprises. We are focused on working with innovative entrepreneurs and companies that have the potential to create moats in technology, product and branding. We understand the challenges of growing companies and are committed to providing flexible, equity and venture debt financing for companies to reach their financial goals.

Nomad Capital Partners

Hambrecht Healthcare Growth Venture Fund is an investment firm

Hambrecht Healthcare Growth Venture Fund

Ocgrow Ventures is an investment firm that manages assets and venture capital investments. Ocgrow engages in a broad range of investment activities and has the flexibility to invest in a wide variety of asset classes. Ocgrow’s venture capital group is focused on several areas including e-commerce, cloud computing, SaaS software, fintech, and other related sectors. Healthcare, cleantech, and other special situations in new growth venture investments are also of great interest to Ocgrow Ventures.

Ocgrow Ventures

Ezaki Glico Co. is a food company headquartered in Osaka, Japan. It has 11 business locations and 23 group companies in Japan, and 12 subsidiaries in nine countries. Ezaki Glico operates a total of 19 plants and has 5,210 employees all over the world. Since the launch in 1922 of the nutritious and fortified Glico caramel in its distinctive red box, the business activities of Ezaki Glico have adhered to the corporate philosophy of ''Enhancing Public Health Through Food.'' Upon the 70th anniversary of Ezaki Glico in 1992, this same spirit and dedication have been incorporated into the revised corporate philosophy of ''A Wholesome Life in the Best of Taste.'' Glico caramel – the company's first product – incorporates the innovative creativeness of Mr. Riichi Ezaki, the company's founder. From the beginning, all personnel working for the company have been dedicated to further enhancing people's health and quality of life. This has led to the expansion of business lines beyond confectionery to include ice cream products, processed foods, desserts, milk products, baby formula, food ingredients, and ingredients for cosmetic and health products.

Ezaki Glico

WestRiver Group is an investment firm that provides integrated capital solutions to the global innovation economy. The firm has investment platforms focusing on the technology, life science, energy, and experiential sectors, with the flexibility to invest in a variety of asset classes and capital structures. WRG’s established network of partners provides access to investment opportunities and thought leadership, and deep operational expertise allows it to work closely with portfolio companies and lead at the executive and board level. WestRiver Group was established in 2002 and is based in Kirkland, Washington, United States. WestRiver Group has adopted the Diversity Term Sheet Rider.

WestRiver Group

WR Hambrecht is a financial services firm that helps companies of all sizes access capital at the lowest cost in order to accelerate disruptive growth. Its philosophy is based on tenants such as identifying companies, helping them raise capital and go public, and delivering market pricing. The company has a wide range of products such as the OpenIPO Auction, the A+ IPO, the OpenBook Auction, and the OpenFollowOn Auction. Their clients are NETSUITE, Google, MORNINGSTAR, and XBiotech and it also offers initial public offering services to companies. WR Hambrecht is a U.S.-based company that was founded in 1998 by William and Robert Hambrecht.

WR Hambrecht

Eastward Capital Partners is a U.S.-based venture debt firm investing in IT, communications, alternative energy, and healthcare companies.

Eastward Capital Partners

Viome

Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age.  The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalized recommendations. Viome was established on October 1, 2016 by Naveen Jain in 	Bellevue, Washington.

<div>Viome focuses on digitizing, decoding, and deciphering human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer. Viome uses a systems biology approach to comprehend the origin and progression of a disease through gene expression (mRNA) analysis with its AI platform. The company develops tests to assess gut and oral microbiome health and provides custom supplement formulas and tailored biotic blends to improve it. These tests are designed to determine how well the user is aging at a cellular level, and nutrition recommendations are designed to optimize the user's specific biological functions responsible for how they're aging internally.</div>

Longevity Tech

Viome prevents and reverses chronic disease by digitizing and decoding each individual’s biology; starting from the gut microbiome. The company claims it is the only company that has clinically approved metatranscriptomic technology in at-home tests to deliver personalized dietary and supplement recommendations based on 50+ biomarkers.&nbsp;

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Viome is a health technology company that focuses on analyzing the human gut microbiome to provide personalized nutrition recommendations and products. It offers at-home test kits that use advanced RNA sequencing to identify the active microorganisms and gene expressions in a user's gut from a stool sample. Using AI, the company analyzes this data to generate detailed reports outlining the customer's gut health, dietary recommendations categorized by "superfoods," foods to minimize or avoid, as well as custom probiotic, prebiotic, and supplement formulations.

Functional Nutrition

Viome secures $25M, hires former Amazon, Groupon, Samsung executive

GlaxoSmithKline

To research and potentially develop interventions for some cancers and autoimmune diseases. The collaboration will allow the companies to study the connection between the gut microbiome and some chronic diseases, like autoimmune disorders.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

To research the prevention of specific chronic diseases.

Viome prevents and reverses chronic disease by digitizing and decoding each individual’s biology; starting from the gut microbiome. The company claims it is the only company that has clinically approved metatranscriptomic technology in at-home tests to deliver personalized dietary and supplement recommendations based on 50+ biomarkers.&nbsp;The company offers various health solution plans that include tests, custom-formulated supplements and personalized biotics. The diagnostic tests analyze the microbiome to provide insights into gut health, oral health, and overall wellness. Viome's flagship is the Gut Intelligence Test, which examines microbial composition from saliva, blood, and stool samples collected via at-home kits.Viome’s Health Sciences division focuses on researching and advancing precision diagnostics and therapeutics platform focused on chronic diseases, cancer, and aging. Viome operates the ViOS platform that uses technology and data from 325,000 human samples to learn about how diseases work. This helps to create new tests and treatments for chronic diseases by studying how genes and microbes in bodies interact.In <a href="https://sp-edge.com/updates/23450">November 2023</a>, the company acquired Naring Health, a digital health and wellness company to enhance personalized health solutions.Key customers and partnershipsThe company has collaborated with pharma companies such as GSK, and Advent Health to carry out research. In July 2019, Viome partnered with Mayo Clinic to study the role of nutrition in disease and explore the potential of personalized diets in managing sleep disorders.&nbsp;In August 2023, the company entered a distribution agreement with pharmacy chain CVS to roll out its gut microbiome testing kit through 200 CVS stores.Funding and financials<a href="https://sp-edge.com/updates/21157">In August 2023</a> the company raised USD 86.5 million in Series C funding from Khosla Ventures, Bold Capital, and WRG Ventures. The funds were used for R&amp;D expansion efforts.

Viome prevents and reverses chronic disease by digitizing and decoding each individual’s biology; starting from the gut microbiome. The company claims it is the only company that has clinically approved metatranscriptomic technology in at-home tests to deliver personalized dietary and supplement recommendations based on 50+ biomarkers.&nbsp;The company offers various health solution plans that include tests, custom-formulated supplements and personalized biotics. The diagnostic tests analyze the microbiome to provide insights into gut health, oral health, and overall wellness. Viome's flagship is the Gut Intelligence Test, which examines microbial composition from saliva, blood, and stool samples collected via at-home kits.Viome’s Health Sciences division focuses on researching and advancing precision diagnostics and therapeutics platform focused on chronic diseases, cancer, and aging. Viome operates the ViOS platform that uses technology and data from 325,000 human samples to learn about how diseases work. This helps to create new tests and treatments for chronic diseases by studying how genes and microbes in bodies interact.In <a href="https://sp-edge.com/updates/23450">November 2023</a>, the company acquired Naring Health, a digital health and wellness company, to enhance personalized health solutions.Key customers and partnershipsThe company has collaborated with pharma companies such as GSK, and Advent Health to carry out research. In July 2019, Viome partnered with Mayo Clinic to study the role of nutrition in disease and explore the potential of personalized diets in managing sleep disorders.&nbsp;In August 2023, the company entered a distribution agreement with pharmacy chain CVS to roll out its gut microbiome testing kit through 200 CVS stores.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

<div>
 
 Viome focuses on digitizing, decoding, and deciphering human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer. Viome uses a systems biology approach to comprehend the origin and progression of a disease through gene expression (mRNA) analysis with its AI platform. The company develops tests to assess gut and oral microbiome health and provides custom supplement formulas and tailored biotic blends to improve it. These tests are designed to determine how well the user is aging at a cellular level, and nutrition recommendations are designed to optimize the user's specific biological functions responsible for how they're aging internally.
 
 
 
 
 Viome is claimed to measure over 10 million data points from expressed genes per sample from microbial (oral and gut) and human cells. Viome offers over 50 health score biomarkers included with its Full Body Intelligence Test. The scores are based on an analysis of all the gene expressions in the body, which can reveal the precise nutrition needed to address inflammation and microbial imbalance.&nbsp;
 
 
 
 
 The company also produces custom-formulated blends and ships them to customers on a monthly basis. These are offered in the form of supplements, gut biotic blends, and oral biotic lozenges. These are personalized to customers based on the results of full-body intelligence, gut intelligence, and oral intelligence tests, respectively.
 
 
 In November 2023, Viome Life Sciences acquired Naring Health, a digital health and wellness company focused on providing access to individualized clinical and molecular data. The acquisition also included Naring Health&rsquo;s health monitoring company, DiscernDx, and food science company Foodome. After the acquisition, Viome intended to enhance its suite of personalized health solutions by using combined resources, including key patents and intellectual property.
 
 
 Key customers and partnerships
 
 
 
 
 Viome entered a partnership with pharmacy chain CVS in August 2023 to expand its product distribution, thereby making its tests available in 200 CVS stores across the US.
 
 
 
 
 Funding and financials
 
 
 
 
 In October 2023, the company raised USD 86.5 million in a Series C funding round co-led by Khosla Ventures and Bold Capital. The company expected to use the funds for business and market expansion.
 
 
 
 
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

Viome is a health technology company that focuses on analyzing the human gut microbiome to provide personalized nutrition recommendations and products. It offers at-home test kits that use advanced RNA sequencing to identify the active microorganisms and gene expressions in a user's gut from a stool sample. Using AI, the company analyzes this data to generate detailed reports outlining the customer's gut health, dietary recommendations categorized by "superfoods," foods to minimize or avoid, as well as custom probiotic, prebiotic, and supplement formulations.The company’s at-home testing kits include 1) the Full Body Intelligence Test for testing over 50 health metrics based on blood, urine, and stool samples; 2) Gut Intelligence Test for testing over 20 gut health metrics based on a stool sample; 3) the Oral Intelligence Test for identifying underlying causes for oral issues based on a saliva sample; and 4) the CancerDetect Test for at-home testing for biomarkers associated with early-stage oral and throat cancer based on a saliva sample. As of July 2024, these tests were priced at USD <a href="https://www.viome.com/products/full-body-intelligence">399</a>, USD <a href="https://www.viome.com/products/gut-intelligence">279</a>, USD <a href="https://www.viome.com/products/oral-health-intelligence">259</a>, and USD <a href="https://cancerdetect.viome.com/?_gl=1*1mayav0*_gcl_au*NzE0NTk0NzA3LjE3MjEzMDgzNDU.*_ga*NjUwOTU2OTAwLjE3MjEzMDgzNDU.*_ga_QBRYR4Y4HG*MTcyMTMwODM0NC4xLjEuMTcyMTMwODY2MC4xMS4wLjA.">599</a> respectively. The Full Body Intelligence and Gut Intelligence Test kits can also be paired with custom supplements provided by Viome to help combat individual deficiencies revealed by test results.In <a href="https://www.prnewswire.com/news-releases/viome-receives-fda-approval-for-its-unique-mrna-technology-and-ai-platform-to-detect-cancers-301285629.html">May 2021</a>, Viome's CancerDetect Test received FDA Breakthrough Device approval for its ability to detect oral and throat cancers from a saliva sample.Key customers and partnershipsIn <a href="https://techcrunch.com/2023/08/18/viome-a-microbiome-startup-raises-86-5m-inks-distribution-deal-with-cvs/">August 2023</a>, Viome partnered with CVS to make its at-home gut tests available at CVS locations throughout the US, increasing accessibility for consumers interested in microbiome analysis.

Youniq Health is a US-based company that has developed an AI-powered app to provide personalized nutrition plans tailored to individual users' health goals, dietary preferences, and biological data. The app utilizes an algorithm that processes various data points, such as blood samples, microbiome tests, genomic information, biometrics, and food preferences, to generate customized recipes and meal plans. These recipes are designed to align with the user's specific objectives, whether it's improving sleep, managing diabetes, managing chronic conditions, or boosting the immune system.A key feature is its ability to create new recipes in real time, complete with accompanying images. The app's AI technology generates these recipes based on the user's personalized data, ensuring that the suggested meals are not only nutritionally optimized but also visually appealing. Recipes provided are optimized so that the user can prepare the meal in less than <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">15 to 20 minutes</a>.To make the recommended recipes more actionable, Youniq has partnered with several grocery retailers, enabling users to have the necessary ingredients delivered to their doorstep within <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">two hours</a>. Additionally, the app <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">can scan the ingredients</a> already available in the user's refrigerator and suggest recipes accordingly, minimizing the need for additional shopping trips.In <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">April 2023</a>, Youniq Health announced its plans to expand into the UK market, recognizing the country's potential for its English-language app.The company noted that as of <a href="https://www.youniq.health/">July 2024</a>, its app was available globally; however, its grocery delivery option was only available to US-based users.Key customers and partnershipsAs of July 2024, the company partnered with employers to offer employees access to its platform, as healthier employees can lead to reduced healthcare costs. Additionally, Youniq partnered with hospitals to provide nutrition programs for patients, assisting them in maintaining optimal diets after procedures.

Youniq

ZOE is a personalized nutrition provider that aims to provide tailored dietary recommendations based on an individual's biological needs. Members begin by requesting at-home testing kits priced at USD 294 as of July 2024, the results of which are analyzed by the company. Based on the analysis of the testing kit, which includes tests for blood fat, gut microbe, and standardized test meals, users can utilize the company’s app to analyze and find meals best suited to their individual needs.Meals analyzed are assigned a ‘ZOE score’ between 0 and 100, with higher scores being more nutritional. Based on these scores, users are able to build meals, discover new recipes, track their individual progress, and combine, swap, and add food to planned meals to optimize their nutrition.Additionally, through the app, users gain access to qualified nutrition coaches for live chats and access educational material curated by scientists.The company additionally offers a wholefood supplement developed using over 30 plants called ‘Daily30+,’ which it offers on a subscription basis of GBP 39 (USD 51) for one month’s worth of servings or GBP 133 (USD 172) for four months’ worth of servings.As of <a href="https://zoe.com/our-science#research-updates">July 2024</a>, the company was also conducting a clinical trial on the effects of a personalized nutrition program on cardiometabolic health. As a part of the study, users could sign up to be participants and would be eligible to receive a blood sugar monitor for tracking the effectiveness of following ZOE’s personalized nutrition program with regard to cardiometabolic health. The monitor is included in the initial testing package if users opt in when ordering the at-home testing kit.

Lifesum is a digital nutrition platform that helps users build healthier eating habits through its innovative app. Founded in Stockholm, Sweden in 2013, the company provides a comprehensive suite of features to track meals, habits, and body measurements, enabling users to achieve their health and wellness goals. As of June 2024, Lifesum has over 65 million users worldwide across 250 countries, supporting 11 languages.The app offers a user-friendly food diary allowing users to log meals by searching a database, scanning barcodes, or manually entering items. It tracks calorie intake, hydration levels, exercise routines, and provides personalized diet plans tailored to individual preferences and objectives, such as ketogenic, high protein, Scandinavian, or Mediterranean diets. Lifesum's premium subscription unlocks additional features like detailed nutrient tracking, advanced analytics, and a vast library of healthy recipes.In <a href="https://www.prnewswire.com/news-releases/lifesum-shakes-up-european-wellness-with-transformative-lykon-acquisition-302171999.html">June 2024</a>, Lifesum announced its transformative acquisition of LYKON, a biomarker-based personalized nutrition company in Germany. This aimed to revolutionize Lifesum's service by integrating LYKON's pioneering technology, enabling users to access personalized nutrition and wellness recommendations based on medical-grade biomarker testing and analysis.Key customers and partnershipsIn addition to offering its services directly to users, Lifesum partners with enterprise clients to offer its solution to employees as part of a work benefit. The company noted that as of <a href="https://www.prnewswire.com/news-releases/lifesum-shakes-up-european-wellness-with-transformative-lykon-acquisition-302171999.html">June 2024</a>, it offered its solution to over 100 enterprise clients, including <a href="https://yulife.com/blog/lifesum-partnership/">YuLife</a>, <a href="https://leadiq.com/c/lifesum/5a1d8afd240000240065b0ce#:~:text=Corporate%20Wellness%20Partnerships%20Lifesum%20has,%2C%20General%20Electric%2C%20and%20PayPal.">PayPal, General Electric, and Amazon</a>.Additionally, the company has collaborated with companies to increase the functionality of its platform.In <a href="https://lifesum.com/page/lifesum-and-openesg-partner-to-connect-nutrition-and-sustainability">August 2023</a>, the company partnered with OpenESG, a global sustainability GenAI platform, to help users see how their dietary choices affect the climate.In <a href="https://lifesum.com/page/lifesum-and-oura-partner-to-connect-nutrition-and-sleep-via-health-connect-by-and">May 2023</a>, Lifesum partnered with smart ring provider ŌURA to provide users with a sleep-tracking feature. The feature allows users to analyze how their diet affects their sleep and vice versa.In <a href="https://www.prweb.com/releases/digital-health-app-lifesum-teams-up-with-amazon-to-bring-nutrition-coaching-to-newly-unveiled-amazon-halo-860278838.html">August 2020</a>, the company partnered with Amazon to offer Lifesum’s nutrition coaching feature through Amazon Halo. Through the partnership, users of Amazon Halo could access nutritional challenges and health content provided by Lifesum.

Lifesum

MyFitnessPal is a mobile app that helps users track their diet and physical activity to achieve health and weight goals. With a database featuring millions of food items, the app enables precise logging of nutritional intake, aiding individuals in making informed dietary choices. It provides a user-friendly interface for recording consumed foods, calculating calories, and monitoring nutrient breakdown, including carbohydrates, proteins, fats, vitamins, and minerals.In addition to diet tracking, MyFitnessPal allows users to log their physical activities, such as running, walking, or gym workouts. Based on the recorded information, the app calculates the calories burned from these activities and updates the overall calorie balance. Users can set personalized goals for weight loss, gain, or maintenance, and the app tracks progress toward these objectives, providing insightful charts and reports.Key customers and partnershipsMyFitnessPal <a href="https://support.myfitnesspal.com/hc/en-us/articles/360032274232-What-kind-of-products-and-apps-work-with-MyFitnessPal">integrates</a> with various fitness trackers and apps, enabling data synchronization and automatic updates. This integration includes popular devices and platforms such as Apple Watch, Fitbit, Garmin, Samsung Health, and Google Fit. By connecting with these third-party services, MyFitnessPal offers users a comprehensive view of their health and activities, fostering a holistic approach to wellness.

MyFitnessPal

Limbo is a digital weight loss and body transformation service that guides users to healthier habits by leveraging real-time biodata from wearables, including a continuous glucose monitor (CGM), an app, and a combination of human coaches and AI. The service is based on over 30 years of research by Co-Founder and Physiologist Tony Martin, focused on understanding how blood glucose levels regulate the body's energy system.Limbo's approach revolves around monitoring users' blood glucose levels and providing personalized feedback and nudges to help them make better food choices and lifestyle adjustments. The goal is to flatten users' blood glucose levels, which Limbo refers to as the "Limbo line" by reducing the consumption of carbohydrates, sugars, and processed foods. This, in turn, is believed to promote weight loss and improve overall health.The service involves wearing a CGM sensor, which continuously tracks users' glucose levels, and a smart wristband that monitors various biometrics, including heart rate, steps, and sleep patterns. Users also receive a smart scale to track their body weight, body fat, and muscle mass. This data is then analyzed by Limbo's AI system and human coaches, who provide tailored feedback and guidance through the Limbo app.As of July 2024, the company operated on a subscription model, initially charging users GBP 295 (USD 381) for access to its services, after which users could choose from several subscription packages ranging from GBP 120 (USD 155) per month to GBP 160 (USD 207) per month. The company also offers a monthly non-subscription package for GBP 195 (USD 252) per month.

Limbo

Providers of tailored dietary recommendations based on an individual's genetics and lifestyle for optimal wellness and disease prevention. This also includes calorie-counting apps that assist with weight loss and management

Designers of tailored dietary plans to address root causes of chronic diseases and symptom management

Companies that develop and offer supplements and nutraceuticals focused on enhancing health, addressing nutrition deficiencies and supporting overall wellness

Companies that provide personalized food services, including medically tailored meals and a marketplace for diverse dietary products to meet individual needs

Companies that offer virtual consultations from dietitians and nutritionists offering guidance via personalized nutrition plans, lifestyle and dietary assessments, and a focus on long-term health and wellness

Some functional nutrition offerings are based on the genomic profiles of individuals to identify personalized solutions

Most functional nutrition companies offer nutrition solutions via digital mediums such as mobile applications; virtual consultations are also a part of the industry

Most functional nutrition companies provide personalized nutrition solutions in the form of meal plans, supplements, and prepared meals

The products/platforms offered by most companies utilize AI/ML to enhance their offering

<div>
 Viome Life Sciences, a startup specializing in passive remote monitoring, has successfully secured USD 25 million in a Series D funding round. Key participants included prominent entities such as Khosla Ventures, Bold Capital, WRG Ventures, and Marc Benioff among others.
 This newly raised capital is intended to be allocated for the inception of a diagnostics division as well as the expansion of current solutions aimed at chronic diseases, cancer, and aging. As part of this strategic development, the company has welcomed Kal Raman to its executive team in the role of chief operating officer (COO). Boasting a diverse professional background, Raman has held notable positions at esteemed organizations such as Samsung, Groupon, and Amazon, where he worked under the direct leadership of Jeff Bezos.
</div>

Viome

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless